Summary of currently available drugs which can be potentially used for treatment of COVID-19
The Table below was published in e-book International Pulmonologist’s Consensus On Covid-19 2nd ed 2020 on April 22nd 2020 (ed. Tinku
Tag: Captisol
Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence
In a pandemic like Covid-19 the urgent need excludes the development of new drugs, “conventional drug in new use” becomes
Eva Pharma, DRL, Biocon and Zydus Cadila added to Voluntary Licensing Agreements for Remdesivir
Gilead has signed non-exclusive voluntary licensing agreements with further generic pharmaceutical manufacturers based in Egypt and India to further expand supply
ALL EYES ON GILEAD
Bloombergs Businessweek published the story on how Gilead scineces prepared for the recently obtained emergency approval of the antiviral drug
Takeda Announces Data from the Phase 2 Trial of SBECD-enabled Pevonedistat Plus Azacitidine
Takeda Pharmaceutical Company Limited announced the results of the Phase 2 Pevonedistat-2001 trial. The study evaluated a cyclodextrin-enabled (SBECD) pevonedistat plus
Ligand CEO Issues Letter to Captisol Customers
Yesterday, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that Chief Executive Officer John Higgins issued a letter to Ligand’s Captisol® customers. The
Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19
Gilead Sciences, Inc. announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This
UK grants early access for Gilead’s remdesivir in Covid-19
The government of the U.K. is granting the country’s equivalent to an emergency use authorization to remdesivir, the antiviral drug
The history of sulfobutylether-beta-cyclodextrin
With this historical paper, prof. Stella and Dr. Rajevski wanted to honor to Dr. Thornsteinn Loftsson, Professor Emeritus at University
First copies of Gilead’s SBECD-enabled remdesivir to start selling in Bangladesh
According to Hindustan Times, Bangladesh’s Beximco Pharmaceuticals Ltd. has become the world’s first company to start selling the generic version